Results 161 to 170 of about 105,814 (267)

Atorvastatin‐Associated Liver Injury: Outcome After Statin Rechallenge

Fundamental &Clinical Pharmacology, Volume 40, Issue 2, March 2026.
ABSTRACT Background Statin‐induced liver injury is frequent and usually not severe. The aim of the present study was to describe the safety of statin rechallenge after atorvastatin‐induced liver injury because it is poorly documented. Methods Cases of liver injury involving atorvastatin were selected from the French pharmacovigilance database ...
Blandine Bertin, Valentine Lacotte, Jean‐Luc Cracowski, Anais Gaiffe, Jérôme Dumortier, Thierry Vial   +5 more
wiley   +1 more source

Harnessing Non‐Covalent Protein–Protein Interaction Domains for Production of Biocatalytic Materials Systems

Advanced Functional Materials, Volume 36, Issue 11, 5 February 2026.
Non‐covalent protein–protein interactions mediated by SH3, PDZ, or GBD domains enable the self‐assembly of stable and biocatalytically active hydrogel materials. These soft materials can be processed into monodisperse foams that, once dried, exhibit enhanced mechanical stability and activity and are easily integrated into microstructured flow ...
Julian S. Hertel, Maria Alessandra Martini, Marius Stoeckle, Annika J. Weber, Kersten S. Rabe, Christof M. Niemeyer   +5 more
wiley   +1 more source

Surface‐Coated Inorganic Nanomaterials for Drug Delivery: Chemical Design, Biomedical Applications, and Mechanistic Insights

Advanced NanoBiomed Research, Volume 6, Issue 2, February 2026.
This review explores how surface‐coated inorganic nanomaterials are chemically engineered for advanced drug delivery. It highlights design principles, coating strategies, and biomedical applications, emphasizing how surface chemistry governs biocompatibility, targeting, and controlled release.
Hossein Daneshgar, Sepideh Ahmadi, Nikzad Abbariki, Navid Rabiee, Sidi A. Bencherif   +4 more
wiley   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Evaluation of changes in the global longitudinal strain for left ventricular function before and after eight weeks of taking high dose of atorvastatin in patients with coronary slow flow phenomenon

BMC Cardiovascular Disorders
Background Coronary Slow Flow Phenomenon (CSFP) is a well-recognized clinical entity characterized by delayed opacification of coronary arteries in the presence of a normal coronary angiogram.
Nakisa Khansari, Amir Mohammad Salehi, Niloofar Mohammadi, Amir Hossein Yazdi, Zahra Sanaei   +4 more
doaj   +1 more source

The Physiology of Lived Experience: And then there was one – the story of a radical nephrectomy

Experimental Physiology, EarlyView.
Michael J. Shattock
wiley   +1 more source

Simultaneous Intracranial and Spinal Hemorrhage Following Tenecteplase Thrombolysis for ST‐Elevation Myocardial Infarction: A Case Report

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Central nervous system (CNS) hemorrhage is a serious complication of intravenous thrombolysis. Tenecteplase, a fibrin‐specific thrombolytic agent, has a lower risk of hemorrhage than other agents. We report the first documented case of simultaneous intracranial and spinal hemorrhage following intravenous administration of tenecteplase.
Thamalee Palliyaguru, Pramith Ruwanpathirana, Praveen Weeratunga, Mythily Aravinthan, Thashi Chang   +4 more
wiley   +1 more source

Low‐Dose Aspirin Induced Gastric Ulcer in a Patient With TIA: A Clinical Caution for Aspirin Therapy Without Gastroprotection

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Balancing the cerebrovascular benefits of low‐dose aspirin (LDA) with its significant gastrointestinal (GI) bleeding risk is a critical challenge in secondary stroke prevention. We describe a cautionary case of a 60‐year‐old male who, 6 months after starting LDA for a transient ischemic attack (TIA), presented with a life‐threatening upper GI ...
Kainat Husain, Muhammad Ibrahim, Fazeela Bibi, Khalil El Abdi, Bilal Aslam, Abdullah Saud, Vohra Maham Hassan, Aminullah Betanai, Muhammad Muneeb, Said Hamid Sadat   +9 more
wiley   +1 more source

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

The High Price of Interrupted Follow‐Up: Catastrophic Progression of Homozygous Familial Hypercholesterolemia—A Case Report and Literature Review

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Familial hypercholesterolemia (FH) is the most common monogenic lipid disorder, primarily resulting from mutations in LDLR, APOB, and PCSK9 genes. These mutations cause persistently high levels of low‐density lipoprotein cholesterol (LDL‐C), predisposing affected individuals to premature atherosclerotic cardiovascular disease (ASCVD ...
Parham Dastjerdi, Mahdieh Aghababaei, Reza Nikfar, Maryam Aghakouchakzadeh, Reza Mohseni‐Badalabadi, Kaveh Hosseini   +5 more
wiley   +1 more source